Zydus receives final approval from the USFDA for Minocycline Hydrochloride Extended-Release Tablets USP, 55 mg, 65 mg, and 115 mg

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) for Minocycline Hydrochloride Extended-Release Tablets USP, 55 mg, 65 mg, and 115 mg (USRLD: Solodyn Tablets, 55 mg, 65 mg, and 115 mg).

Minocycline Hydrochloride Extended-Release is used to treat moderate to severe acne in people 12 years and older. Minocycline belongs to a class of drugs known as tetracycline antibiotics. The product will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad (India).

Minocycline Hydrochloride Extended-Release Tablets USP, 55 mg, 65 mg, and 115 mg had annual sales of USD 0.7 mn in the United States (IQVIA MAT April 2023).

The group now has 372 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 554.35 as compared to the previous close of Rs. 550.80. The total number of shares traded during the day was 34724 in over 2131 trades.

The stock hit an intraday high of Rs. 562.15 and intraday low of 550.05. The net turnover during the day was Rs. 19286494.00.

(*as of 31st March 2023)

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 USFDA FinalApproval MinocyclineHydrochloride ExtendedReleaseTablets